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Objective: The aim of this study was to explore the views of community pharmacists par-
ticipating in the pilot of a secure online platform in Wales, the Choose Pharmacy application 
(CPA), with particular interest in the electronic Discharge Advice Letters (e-DALs) and online 
Discharge Medicines Review (DMR) form.
Materials and methods: A qualitative approach with semi-structured interviews was adopted. 
A gatekeeper from National Health Service Wales Informatics Service identified 35 pharmacies, 
of the 43 pharmacies where the CPA had been implemented, that had completed at least one 
DMR, and these were therefore invited to an interview.
Results: A total of 17 pharmacists were interviewed. Overall, the results were positive and CPA 
and e-DAL were perceived to facilitate continuity of care between care settings. The design and 
usability were perceived as good as pharmacists could navigate the CPA without problems; many 
felt this was due to the level of training they had received. Many pharmacists were happy for 
other services to be included on the platform due to its ease of use and automatic reimburse-
ment. Several pharmacists felt that communication between primary and secondary care can 
be further improved as the uptake of e-DAL increases.
Conclusion: CPA was found to streamline the completion of online DMR improving continu-
ity of care between primary and secondary sectors, which in turn should improve patient safety 
on discharge from hospital.
Keywords: continuity of care, electronic Discharge Advice Letter, Discharge Medicines Review
Introduction
Medication-related information is sometimes incomplete when patients transfer 
between health care settings such as at hospital admission and hospital discharge,1–3 
often because of miscommunication between care providers.4,5 Inadequate documenta-
tion at discharge can negatively impact on the quality of subsequent patient care,2,6–8 
even leading to rehospitalisation.9,10 In addition, concerns have been raised by general 
practitioners (GPs) regarding the completeness and timeliness of receipt of discharge 
information.3,11–13 The need for community pharmacies to receive discharge informa-
tion has also been noted.14,15
There has been increasing interest worldwide in addressing continuity of care for 
patients by introducing standards and templates for discharge information,16,17 and 
integrating pharmacists in hospital and post-discharge patient support.18,19 Standardized 
electronic transfer of medication-related issues has been proposed as a way to improve 
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information transfer and facilitate continuity of care.6,15,20–22 
However, there does not seem to be a formal process for the 
reconciliation of medicines on discharge from hospital, and 
the role of the community pharmacist in such a process is 
often overlooked by other health care professionals.3
In Wales, the Discharge Medicines Review (DMR) ser-
vice was established in November 2011 to improve the man-
agement of medicines following a patient being discharged 
from a care setting.23 The community pharmacist undertakes 
the service and receives a fee of £37 per patient. The service 
consists of two parts: part one is patient identification and 
reconciliation of medicines following discharge and part two 
is designed to support adherence to medication. The com-
munity pharmacist undertaking the DMR identifies, records 
and resolves any differences between the discharge prescrip-
tion from hospital and the first prescription written by the 
GP. Examples of such differences may include a medicine 
being restarted in the community that was discontinued by 
the hospital, a wrong strength being prescribed or a wrong 
formulation. These are documented on the DMR form, and 
once complete the pharmacist inputs the relevant details into 
a national database to claim payment for the service. Patients 
are recruited for the service either as a self-referral, by the 
pharmacy knowing the patient has been in hospital, or by 
referral from a health care professional. In the DMR evalu-
ation,14 81% of DMRs (n=14,649) had at least one difference 
between the discharge prescription and the first prescription 
post discharge received by the community pharmacist. The 
most common difference (52%) was a medicine discontinued 
or restarted. The discrepancy rate was 1.3 per DMR (range 
1.10–1.44). While many community pharmacists were sup-
portive of the service, they identified a few barriers to its 
implementation. These were the difficulty in identifying 
eligible patients as they were not informed the patient had 
been in hospital, a lack of access to discharge information 
and the paperwork not being user-friendly.
Another initiative supported by the government in Wales 
to strengthen interdisciplinary collaborations and address 
continuity of care issues was the development by National 
Health Service Wales Informatics Service (NWIS) of the 
Medicines Transcribing and electronic Discharge (MTeD) 
system. MTeD, which was piloted in 2012 and is now being 
rolled out across Wales, allows hospital pharmacists to 
update the patient’s medication list which is then imported 
it into a Discharge Advice Letter (DAL), that is then subse-
quently provided as a hard copy to patients and electronically 
transferred to the patient’s GP on the day of their discharge 
(Figure S1).
After the DMR evaluation, in April 2015, NWIS devel-
oped a pharmacy-specific electronic version of the DAL 
(e-DAL) that includes information about the patient’s medica-
tion and any changes that have been made during the patient’s 
hospital stay.24–26 If a patient consents, this e-DAL can be 
accessed from a secure online platform by a pharmacist in a 
nominated community pharmacy.27 The medicines’ informa-
tion in the e-DAL can be imported into a newly developed 
online DMR form within the platform which was integrated 
automatically with the process for claiming the DMR fee. 
In order for the community pharmacist to know information 
is available to access, since September 2015, the pharmacy 
receives an email asking them to access the secure platform 
to view the e-DAL. This platform, which was originally 
developed in Wales for the Common Ailment Scheme, is 
called the Choose Pharmacy application (CPA). Training 
on how to use CPA was undertaken by pharmacists in all 
pharmacies where CPA had been implemented.
The functionality of the e-DAL, email notification and 
integration of the e-DAL with the online DMR form was 
piloted in three health boards across Wales. Before further 
rollout across Wales, feedback was required to inform its 
future development. Therefore, the aim of this study was to 
explore community pharmacists’ views on the CPA for the 
provision of pharmacy services, with particular interest in 
the e-DALs and online DMR form.
Materials and methods
A qualitative methodology was adopted to explore the 
pharmacists’ opinions. Figure 1 outlines the main steps in 
the methodology.
Ethical approval
The Cardiff School of Pharmacy and Pharmaceutical Science 
Research and Ethics Committee (SREC) granted full ethical 
approval (October 2015).
Data collection
Sampling method, recruitment and consent
While 43 community pharmacies across three health boards 
had access to the CPA, information from National Health 
Service (NHS) Wales Shared Services Partnership (NWSSP-
Primary Care Services [PCS]) showed that between April 
and October 2015, 35 pharmacies were completing DMRs 
electronically using the CPA. As eight pharmacies had not 
completed any DMRs, they were excluded from the study.
The gatekeeper from NWIS emailed all the 35 eligible 
pharmacies. After a follow-up email, all nonresponders were 
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telephoned by the gatekeeper. Due to time restrictions, all 
pharmacists who agreed to participate were immediately 
contacted by either of the two researchers at Cardiff Uni-
versity by telephone to arrange an interview. A participant 
information sheet and consent form were provided via email 
preceding the interview. This information included reasons 
for undertaking the research and interviewer characteristics. 
No follow-up of nonrespondents was completed, and hence 
reasons for nonparticipation are unknown.
Interviews
Face-to-face semi-structured interviews were conducted 
from November 4, 2015, to December 16, 2015, by two 
female researchers, completing a Masters level project, at a 
time and location most convenient for the pharmacist. The 
researchers received training followed by practice interviews 
prior to commencement of the study. No prior relationship 
to the participants was present. The interviews were audio 
recorded using a dictaphone; full informed consent was 
obtained prior to recording the interview and no one else was 
present besides the participant and the researcher. No repeat 
interviews were carried out.
Research instrument tool
An interview schedule was designed and piloted to minimize 
bias during the interviews (Figure S2).28 There were three 
main constructs; opinions were explored on CPA in general, 
on e-DALs and DMRs. The participant was not restricted to 
these areas, and several open-ended questions were included 
at the end of the interview to allow the pharmacist to talk 
more generally.
Data analysis
The audio recordings were transcribed ad verbatim using 
SpeechExec software.29 Once transcribed, the data were 
quality assured and anonymized to ensure confidentiality was 
maintained. Both researchers coded the data independently 
before combining into coding that was subsequently checked 
by the wider research team. Inductive thematic analysis was 
used to identify and analyze themes.30
Results
Responses were received from 21 of the 35 eligible pharma-
cies. The first 17 pharmacists who responded were inter-
viewed (49%), due to time constraints. The final sample 
included pharmacists from the three health boards, with a 
variety of experience using CPA, and the number of DMRs 
conducted. Interviews lasted between 20 and 45 minutes 
and all questions followed the same guide. Table 1 outlines 
relevant characteristics of pharmacists interviewed as part of 
the research. Table 2 presents the main themes and a selec-
tion of subthemes after thematic analysis of the data, with 
example quotes for each. The full table with subthemes and 
representative quotes is included in Table S1.
Uptake of e-DALs
A total of 14 pharmacists highlighted a lack of e-DAL use 
in secondary care, either because there were not enough 
wards using the system or a perception that the system is 
not being utilized appropriately at ward level. Many phar-
macists felt positively about the use of e-DALs in future 
despite not having received any before the interviews were 
conducted.
• Participant information sheet and consent form designed.
• Semi-structured interview schedule designed; use of open-ended
   questions
• Invitation email sent through gatekeeper.
• Pharmacists responding positively to the gatekeeper contacted and
   interviews arranged.
• Participant information sheet and consent form sent out via email.
• Face-to-face interviews conducted and audio recorded.
• Interviews transcribed ad verbatim.
• Data analyzed by thematic analysis 
Figure 1 Methodology overview.
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Several pharmacists hoped that an increased uptake of 
e-DAL would be beneficial to both them and their patients.
Information in e-DAL vs. DAL
Most pharmacists preferred using the e-DAL via the CPA to 
receiving a paper DAL, stating that previous problems with 
incomplete information were now obsolete. Several pharma-
cists liked that all the information was displayed on one, easy 
to view page. The majority of pharmacists also felt that the 
e-DAL overcomes transcription errors that were common with 
paper DALs and liked the fact they could print the e-DAL out.
Usability of the CPA
Despite the teething issues, and some input procedures 
perceived as laborious, it was recognized that the system is 
straightforward to use. It was highlighted that the training pro-
vided, even though different between health boards, was pivotal 
in increasing the pharmacists’ confidence in using the system.
Patient confidentiality
All pharmacists interviewed had no concerns regarding 
patient confidentiality when sharing data by using the 
 application, and deemed it to be secure. It was also noted that 
patients did not express any concerns over secondary care 
sharing their discharge information via CPA, and agreed to 
provide consent prior to pharmacists accessing their e-DAL.
Impact of electronic DMR (e-DMR) 
service
Many pharmacists re-emphasized the importance of the DMR 
service with some stating it was the most important service 
they had to offer patients, as they believe it improves patient 
safety by reducing medication errors.
Most pharmacists believed the electronic version of the 
DMR to be superior to the paper version. When an electronic 
copy of the DAL was available, the medication would auto-
matically populate onto the DMR form reducing inputting 
time and potential for medication errors.
Communication
Several community pharmacists felt that communica-
tion between hospitals, GP surgeries and patients has not 
improved yet, especially during the patient discharge process. 
All but one pharmacist believed that communication had not 
improved between health care practitioners in primary and 
secondary care. Many pharmacists were only contacted by 
hospitals if a patient who required a monitored dosage system 
(MDS) was being discharged.
Expanding the CPA
Out of 17 pharmacists, 13 believed that additional services 
should also be made available via the CPA with all services 
amalgamated on one application; information on the ser-
vices conducted in community could also be shared with the 
community pharmacy patient medication record (PMR) and 
directly with the GP surgeries.
Discussion
The aim of the study was to explore community pharma-
cists’ opinions on CPA, e-DALs and the online DMR form. 
Overall, the results were positive. The development of CPA 
has allowed the safe electronic transfer of medication-related 
information to community pharmacies; the need for which 
has been highlighted in the literature.15 The pharmacists inter-
viewed in our study perceived the design and usability of CPA 
as good as pharmacists were able to navigate the application 
without problems. Many felt this was due to the level of train-
ing they had received. The fact that many of the pharmacists 
were happy for other services to be included on the platform, 
due to its ease of use and automatic reimbursement, also dem-
Table 1 List of participants interviewed
Participant 
code
University 
Health 
Board*
Number 
of e-DAL 
received**
Number of DMRs 
conducted by 
pharmacy using 
online form***
A1 1 1 15
A2 1 1 36
A3 1 0 3
A4 2 2 34
A5 2 0 3
A6 1 1 3
A7 2 2 30
A8 2 0 36
A9 3 0 1
A10 3 10 3
A11 3 0 56
A12 3 2 20
A13 3 1 8
A14 3 0 87
A15 3 3 5
A16 2 1 6
A17 2 26 62
Notes: *Each health board has been anonymized. **Number of e-DALs stated 
in this column refers to the number that the interviewee had access to from the 
hospitals between the introduction of the scheme in April 2015 and October 2015. 
***Number of DMRs stated in this column was obtained from the gatekeeper and 
refers to the number of DMRs the pharmacy completed using the online form and 
submitted for payment between the introduction of the scheme in April 2015 and 
October 2015. A subset of these DMRs was completed using the e-DAL, as detailed 
in third column of the table.
Abbreviations: DMR, Discharge Medicines Review; e-DAL, electronic Discharge 
Advice Letter.
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onstrates their support for CPA. While not formally evaluated 
in this research, the community pharmacists did express that 
patients did not seem concerned about providing information 
on their medicines via a secure online platform. The chal-
lenge for developing secure online platforms will always be 
achieving a balance between protecting patient information 
and at the same time not creating excessive barriers for the 
pharmacists accessing patient data; the latter was mentioned 
by some pharmacists in the interviews.
The results demonstrated that the pharmacists felt that the 
e-DAL had improved the quality and completeness of infor-
mation provided to them and allowed the DMR process to be 
more efficient as they no longer were required to manually 
input medicines into the DMR form. This is encouraging as 
Table 2 Themes, subthemes and representative quotes from the thematic analysis of the data
Theme 
number
Themes and 
subthemes
Representative quotes
1 Uptake of e-DALs
Uptake in 
secondary care
“If it could be rolled out onto more wards overtime then it would be much better for us and much better for the 
patient.” (A6)
“I can just see so much potential if it got rolled out properly.” (A17)
“The wards that are using it, are they using it to its full advantage?” (A7)
2 Information in e-DAL vs. DAL
Completeness “There is no chance of any sort of errors happening on the discharge because we are getting the exact 
information, the right dosages, we can look at it, print it out which is much easier [than the DAL].” (A6)
“I think (the e-DAL) is much better than what we use to have (DAL) because not only do you get the list of 
medication, you get what has stopped, what has changed, what has started so I’m very happy with the quality of 
the e-DAL.” (A15)
Presentation “Again it’s so much clearer on the electronic version than it was on the paper version, having to go through all 
the pages, it’s all there on one page.” (A13)
“you’re [sic] avoiding having to try and read doctor’s handwriting.” (A3)
“We can look at it, print it out which is much more easier than trying to get hold of the DAL from patients.” (A6)
3 Usability of the CPA
Training “I had a small training session with the people from the health board and after that I didn’t need to refer to the 
manual. I didn’t need to call them up for any assistance with anything; it was fairly self-explanatory once you got 
in and starting using it.” (A4)
4 Patient confidentiality
Patient consent “It’s fine, it’s well um, we get patients to sign application form and patients are well aware of what they are 
signing up for so as far as we are concerned it’s really confidential.” (A6)
5 Impact of e-DMR service
Link to e-DAL  “It’s just so much quicker with the e-DAL because you don’t need to write in the medicines because it sort of 
does it itself and also it sort of like reduces human error.” (A17)
Patient safety “Patient safety (important service) because we do see quite a lot of errors or quite a lot of drugs that have been 
missed from, dosages that we can pick up so easily which obviously makes continuity of care for the patient 
seamless. Yes, so it’s one of the most valuable services, simply because we want to stop people going back into 
hospital at the end of the day.” (A2)
6 Communication
Patient “You know I think it’s much better if people are educated to bring their DAL into the pharmacy.” (A12)
Hospital “No nothing has changed at all [communication]. I mean every single week we’ve had someone that [sic] have 
realized they only have 3 or 5 days’ supply from hospital and they haven’t made that arrangement. They don’t 
know, it is not explained to them.” (A16)
“...the hospital will identify them as somebody who has a tray from us they’ll always contact us prior to discharge 
to say ‘you’ve got a tray patient coming out with, there’s been X change to their medication’. They’re only 
patients they will notify us of.” (A4)
“We haven’t been getting the e-DALs through but certainly the communication, like I was saying from the 
hospital to us has certainly improved since these trials.” (A5)
GP surgery “We don’t have to go out to the surgery and pull the discharges in, um, even though luckily they do, they play 
ball with us no problem.” (A2)
“We rarely see the patient actually bring in the discharge sheets in themselves. It’s normally sent from the GPs 
and some of the GPs themselves are reluctant to give the information out. (A6)
7 Expanding the CPA
“The more services we can get by the function [CPA] where we can do it straight away there the better.” (A10)
“I’d like it [services] all through one system, Why make it more complicated?” (A14)
Abbreviations: CPA, Choose Pharmacy application; e-DALs, electronic Discharge Advice Letters; e-DMR, electronic Discharge Medicines Review; GP, general practitioner.
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the completeness and timeliness of discharge information is 
often cited as one of the main issues associated with continu-
ity of care for patients between care settings.3,11–13 The MTeD 
system that generates the e-DAL and the discharge letter to 
GPs has been designed so that the end user can populate their 
GP medication record or the DMR form with the medicines 
and hence prevent any transcription errors. This is important 
as just having a record of the medicines does not necessarily 
improve the inclusion of the medicines in the GP record.31 
Systems need to be developed to help the process to be safe 
and efficient.
Due to the limited rollout of MTeD within the health 
boards at the time of this study, the number of e-DALs sent 
to community pharmacists was relatively low. However, it 
is encouraging that those community pharmacists who had 
received an e-DAL agreed that e-DALs were superior to 
paper-based DALs. These results are in line with previous 
research by Pocklington and Al-Dahir32 who demonstrated 
that discharge summaries completed electronically have 
higher completion rates than the paper version, although the 
level of detail provided is dependent on the practitioner com-
pleting the DAL. Their results also showed that the electronic 
version of the DAL is more likely to be fully completed and 
sent promptly.
As MTeD is implemented in more hospitals across Wales, 
the ability for community pharmacists to receive an e-DAL 
increases. However, this still depends upon the engagement 
of the hospital pharmacy team referring patients for a DMR. 
Hodson et al14 in their evaluation of the DMR scheme identi-
fied that often it was the patients using an MDS that were 
referred for a DMR, even though the criteria for a DMR are 
either patients on four or more medicines, changes in medi-
cation, professional judgment or patients using monitored 
dosage systems (MDS). To help erode the continuity of care 
issues, pharmacy teams within the hospital sector need to 
take responsibility for transferring good quality and timely 
information on a patient’s medicines and any changes to their 
regimen to GPs and community pharmacists. In the study 
by Redmond et al,3 where they asked GPs and community 
pharmacists their opinions on medication management at 
transitions of care in Ireland, both the GPs and the community 
pharmacists were in favor of the hospital pharmacist play-
ing a further role in this area. They also felt that the role of 
the community pharmacist should be expanded to identify 
any prescribing errors following transition from one sector 
to another; this role identified is the role of the community 
pharmacist plays in the DMR scheme in Wales.
Conclusion
The development in Wales of the DMR service, e-DAL for 
community pharmacists and the CPA addresses many of the 
barriers to continuity of care reported in the literature.3–5,11–13,15 
The development of a secure online platform that community 
pharmacists find easy to access and navigate and patients 
seem to have confidence in allows further developments in 
this area to be made. There is much interest in the UK in 
developing the role of the community pharmacist, for them 
to provide a more clinical service. Governments are acknowl-
edging the importance of pharmacists being granted access 
to individualized patient records,33,34 to help patients and to 
try to reduce medicines-related readmissions. A platform 
such as CPA would provide a secure way for this to occur. 
When developing services to help meet the continuity of care 
agenda, it is important to include end users of the system in 
the design and to regularly obtain feedback. From our experi-
ence, this has really helped to further develop the systems, 
so that not only is information transferred electronically to 
GPs and community pharmacists in a secure way but also it 
allows them to import the information within the electronic 
format into their systems easily, meaning that information 
on patient’s medication is up-to-date.
Limitations
There are a number of limitations to this study. First, the study 
was designed to only interview those pharmacists who had 
used the CPA to complete DMRs electronically. Eight phar-
macies within the three health boards who had implemented 
CPA but not completed electronic DMRs were therefore not 
invited to participate. An interview with them may have been 
interesting specifically to explore some fundamental barriers 
in engaging with the system.
The second limitation was the small number of e-DALs 
that had been sent to the community pharmacies; this may 
have impacted upon the ability of the interviewees to com-
ment on this development. The small number of e-DALs 
may be accounted for by the delay in the email notification to 
community pharmacies “going live” and the rollout of MTeD 
in each health board, resulting in only a limited number of 
wards using the application at the time of the study.
Of the 35 pharmacies eligible to be included in the study, 17 
participating pharmacists were interviewed. No follow-up of 
nonrespondents was completed. The fact that not many e-DALs 
had been sent to community pharmacies may have meant that 
the pharmacists had little opinion concerning the topic and 
therefore had no motivation to participate in the research.
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While only half of the eligible pharmacists (n=17) were 
interviewed due to data gathering having to occur over 
a 4-week period, no new themes emerged after the 13th 
interview. Therefore, it may not have been beneficial to 
complete further interviews. Of those interviewed, there 
was a selection across the three health boards, and a variety 
in the number of e-DALs received and DMRs completed. 
Therefore, we believe that the interviews provided an 
overview of the opinions and issues regarding the CPA and 
completion of DMRs.
One further limitation was that some pharmacists who 
had agreed to be interviewed lacked time to participate 
in an interview within the private consultation room. The 
interview was therefore conducted in the dispensary with-
out an audio recording. Notes were taken during and after 
the interview to ensure the data gathered were accurate. 
However, some information may have been inadvertently 
omitted.
Recommendations
One objective was to determine pharmacists’ individual views 
on what could be improved. The feedback included enhance-
ments that could be made to e-DALs, e-DMRs and to the CPA. 
From the results gathered, Table 3 represents recommendations 
made by the pharmacists.
Future work
MTeD and e-DAL need to be rolled out across Wales so that 
all wards in the hospitals are using it. This will allow high-
quality, timely information to be communicated to the patient, 
GP and community pharmacist, which should result in safer 
management of medicines at discharge from hospital. As of 
May 2017, MTeD has been implemented in 156 wards across 
five health boards, with around 2,000 e-DALs per week being 
sent to GPs. In April 2017, there were 177 DMRs completed 
by 47 community pharmacies using the CPA and of these 98 
(55%) were completed using an e-DAL.
While those interviewed were complimentary about CPA 
and the developments, further qualitative studies should be 
completed with pharmacists who have not used the system, 
to identify if there are any barriers to using it and how to 
ensure maximum engagement with it.
This is particularly important as NWIS has now secured 
funding from the Welsh Government to roll out the CPA to all 
community pharmacies in Wales by March 2020. One of the 
recommendations from this study is for CPA to encompass 
additional services, so that all services can be accessible 
through the same application. Currently, NWIS is developing 
the CPA to provide access to the Welsh GP Record to support 
the provision of the Emergency Medicines Supply (EMS) 
service, also to record the supply of emergency hormonal con-
traception and administration of influenza vaccination. Further 
services via the CPA are being considered. It is also planned 
to share appropriate information from CPA electronically with 
patients’ GPs, PMR systems and with hospital-based health 
care professionals through the Welsh Clinical Portal.
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Table 3 Pharmacists’ recommendations for improvements
Improvement Recommendation
Location Remove the need to confirm IP address as it is time-consuming and there are other barriers to ensure 
patient confidentiality is maintained
Training Standardize training so that every pharmacist has same level of training
Additional information on e-DAL Ensure that e-DALs contain the same level of details as paper DAL
Print functionality Add a print function to enable pharmacists to print the e-DMR if needed
Increase e-DAL accessibility Increase the accessibility of e-DAL through additional wards and hospitals
Suggested medication A drop-down box of suggested medication similar to that on the PMR should be made available. This will 
reduce the time for pharmacists to type each medication
Audit functionality Insert a functionality which can audit the number of DMRs completed
Records Incorporate a functionality whereby pharmacists can re-access DMRs once they have been claimed to 
provide a record of the patient’s history
Additional services Enhance the CPA to encompass additional services
Abbreviations: DMR, Discharge Medicines Review; e-DAL, electronic Discharge Advice Letter; e-DMR, electronic DMR; PMR, patient medication record.
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Supplementary materials
Figure S1 Example of an e-DAL.
Abbreviation: e-DAL, electronic Discharge Advice Letter.
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Interview schedule
Opening
Date: Time:
Face-to-face/phone interview
Interview length:
Introduction: Thank you for taking part in this study. I can assure you that the information provided will remain confidential. I would 
like your permission to audio record this interview; this is to have an accurate set of data your response and opinions. 
If you don’t have any further questions, I would like to briefly remind you of the purpose of this research as outlined in the 
information sheet you received previously. Only a few pharmacists have tested out the CPA, and before using it throughout Wales 
this application needs to be evaluated. We are interested in evaluating this pilot, regarding feasibility and usefulness of e-DALs and the 
online DMR form. 
I would like to ask you some questions to help us reflect on the good and the not so good points of the application, and allow us to 
improve its quality.
The interview should take about 20–30 minutes. 
1.  What do you think about the CPA?
What about the design?
What about the usability?
Has the application helped you or hindered you? Could you please explain your answer?
What do you think about the patient confidentiality with this application?
Which additional services would you like to see made available in the application?
So, to sum up, for you the application is ………, am I right?
Now let’s talk about the e-DAL.
2.  What do you think about the e-DAL provided via the application?
What about the quality of the e-DAL?
How would you compare the e-DAL with the paper version 
Moving on to the DMR.
3.  What can you tell me about the DMRs you conducted with the application? 
What about the time spent to complete the DMR?
How would you compare the DMRs you conducted with and without the application?
4.  Overall
You have discussed a lot of positive and not so positive aspects of the application, what are the main thoughts you are left with?
Content-mining questions: probes
Probe Question
Amplificatory Can you tell me more about...? Can you give me an example of What exactly do you mean by
Exploratory How does that make you feel Why do you think it is important to Does that help you in any way
Explanation What makes you say that What was/is about...that made you  
feel like
Clarification Could you explain what you  
mean by
In what way do you mean that
Closure
1. Thank you we have covered a lot today, but do you think there is anything that we have missed out? 
2. Do you have any further comments about what we have discussed or about the research in general? 
3.  If you have any further questions or would like more information about the study the contact details are on the information sheet. 
Thank you.
Figure S2 Exploring pharmacists’ views on the integration and use of e-DAL within the community pharmacy setting.
Abbreviations: CPA, Choose Pharmacy application; DMR, Discharge Medicines Review; e-DAL, electronic Discharge Advice Letter.
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Table S1 The full list of themes, subthemes and representative quotes from the thematic analysis of the data
Theme 
number
Themes and 
subthemes
Representative quotes
1 Uptake of e-DALs
Uptake in secondary 
care
“If it could be rolled out onto more wards overtime then it would be much better for us and much better for 
the patient.” (A6)
“I can just see so much potential if it got rolled out properly.” (A17)
“The wards that are using it, are they using it to its full advantage?” (A7)
Registering patients 
on the application
“We have a very big amount of blister pack [multi-compartment compliance aid] patients so we kind of know 
[sic] those who go in and out of hospital so we registered them.” (A17)
 “We did when it first came out [register]. We thought yes but it is really [sic] difficult because you’re also 
saying ‘I know you’re perfectly healthy but when you do eventually’ it is a really [sic] delicate subject” (A16)
2 Information in e-DAL vs. DAL
Completeness “There is no chance of any sort of errors happening on the discharge [sic] because we are getting the exact 
information, the right dosages, we can look at it, print it out which is much easier (than the DAL).” (A6)
“I think [the e-DAL] is much better than what we use to have (DAL) because not only do you get the list of 
medication, you get what has stopped, what has changed, what has started so I’m very happy with the quality of 
the e-DAL.” (A15)
Presentation “Again it’s so much clearer on the electronic version than it was on the paper version, having to go through all 
the pages, it’s all there on one page.” (A13)
“You’re [sic] avoiding having to try and read doctor’s handwriting.” (A3)
“We can look at it, print it out which is much more easier than trying to get hold of the DAL from patients.” (A6)
3 Usability of the CPA
Training “I had a small training session with the people from the health board and after that I didn’t need to refer to the 
manual. I didn’t need to call them up for any assistance with anything; it was fairly self-explanatory once you got 
in and starting using it.” (A4)
System “Since they’ve updated (the software), its quite straightforward to get onto (the application).” (A5)
“Over the last couple of months or even longer I haven’t had any problems at all with crashing or losing 
information so no it’s been fine.” (A2)
 “Well with the ease of it, it’s very straightforward as well.” (A13)
Time “…some of the procedures involved are very laborious. I find that when I’m doing a choose pharmacy 
consultation with the patient I have to spend too much time concentrating on ticking these boxes on the 
computer system and not enough time with the patient.” (A10)
4 Patient confidentiality
Logging in and 
logging out
 “I like the fact that if you do forget to sign off, it does automatically sign you off.” (A15)
Password “I think it has high security level and it won’t let us, we have to re-input our password every time and we have 
to change the password on a frequent basis and it has to be a strong password.” (A10)
 “We’ve got individual passwords so there’s only myself and the other pharmacist who could access it, so 
nobody could get into it accidentally.” (A5)
Patient consent “It’s fine, it’s well um, we get patients to sign application form and patients are well aware of what they are 
signing up for so as far as we are concerned it’s really confidential.” (A6)
Location “We always [access the application] in a secure place.” (A8)
5 Impact of e-DMR service
Link to e-DAL  “It’s just so much quicker with the e-DAL because you don’t need to write in the medicines because it sort of 
does it itself and also it sort of like reduces human error.” (A17)
Patient safety “Patient safety (important service) because we do see quite a lot of errors or quite a lot of drugs that have been 
missed from, dosages that we can pick up so easily which obviously makes continuity of care for the patient 
seamless. Yes, so it’s one of the most valuable services, simply because we want to stop people going back into 
hospital at the end of the day.” (A2)
Audit “Um, what don’t like I’m not sure if you can see it somehow but I like to see how many discharge reviews we’ve 
done so far.” (A1)
Records “You can’t go back into it and check what you’ve done. If somebody comes to see you in 2 months, you’ve 
submitted your claim for that DMR and I can’t access it so you’ve got to have a paper copy and again the system 
doesn’t print so you can’t make a copy from that system.” (A12)
“It claims it automatically so you don’t have to do it all on paper and then put it into NECAF so that saves a lot 
of time.” (A2)
(Continued)
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Theme 
number
Themes and 
subthemes
Representative quotess
6 Communication
Patient “You know I think it’s much better if people are educated to bring their DAL into the pharmacy.” (A12)
Hospital “No nothing has changed at all [communication]. I mean every single week we’ve had someone that [sic] have 
realized they only have 3 or 5 days’ supply from hospital and they haven’t made that arrangement. They don’t 
know, it is not explained to them.” (A16)
“ …the hospital will identify them as somebody who has a tray from us they’ll always contact us prior to 
discharge to say ‘you’ve got a tray patient coming out with, there’s been X change to their medication’. They’re 
only patients they will notify us of.” (A4)
 “We haven’t been getting the e-DALs through but certainly the communication, like I was saying from the 
hospital to us has certainly improved since these trials.” (A5)
GP surgery “We don’t have to go out to the surgery and pull the discharges in, um, even though luckily they do, they play 
ball with us no problem.” (A2)
“We rarely see the patient actually bring in the discharge sheets in themselves. It’s normally sent from the GPs 
and some of the GPs themselves are reluctant to give the information out. (A6)
7 Expanding the CPA
 “If you see a pattern and the GP or practice nurse can see a pattern, they can ask the question of has this 
patient been referred for a sexual health check, as the information will be there (on the portal).” (A13)
 “I can’t see why [the EHC service] can’t be on the system as well so the GPs are aware of how often our 
patients are using things like the EHC.” (A13)
“The more services we can get by the function [CPA] where we can do it straight away there the better.” (A10)
“I’d like it [services] all through one system, Why make it more complicated?” (A14)
 “I’m quite happy the way that other services are recorded at the moment.” (A1)
Abbreviations: CPA, Choose Pharmacy application; DAL, Discharge Advice Letter; e-DALs, DALs; e-DMR, electronic Discharge Medicines Review; EHC, emergency 
hormonal contraception; GP, general practitioner; NECAF, National Electronic Claim and Audit Forms.
Table S1 (Continued)
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